Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Henry Meds is a telehealth company that sells subscription weight-loss, hormone, and sexual-health care, with medicines like compounded GLP-1s shipped to customers' homes.
Henry Meds is an online health company that treats the kind of problems people would rather not discuss in a crowded waiting room: extra weight, hormone changes, thinning hair, and erectile dysfunction. You sign up on its website, meet a licensed clinician over video, and if a prescription makes sense, the medicine shows up at your door. Customers pay a monthly subscription rather than buying each visit and each refill separately.
The business is built on a simple gap in the American health system. Getting a prescription for a weight-loss drug or hormone therapy the traditional way can mean weeks of waiting for an appointment and a hefty bill. Henry Meds sells speed and convenience instead. Its biggest draw has been compounded versions of GLP-1 drugs — the same class of medicine as Ozempic and Wegovy, made by compounding pharmacies rather than the big drugmakers. That matters because the brand-name versions have been expensive and sometimes hard to find. Henry Meds also offers testosterone and menopause hormone therapy, hair-loss treatment, and ED care. The money comes from subscriptions, not from the medicine itself. Customers pay a flat monthly fee that covers the clinician visit and ongoing support, plus a separate charge for the drugs. That model made the company one of the better-known names in a crowded field of telehealth weight-loss startups, alongside competitors like Hims & Hers and Teladoc. It has raised venture money and grown quickly on the back of the GLP-1 boom.
The big risk is regulation. Compounded GLP-1s exist in a legal gray zone: once the brand-name drugs are officially declared in ample supply, regulators can shut down large-scale compounding, which would undercut a core Henry Meds product. The company has responded by expanding into other treatments and, in some cases, prescribing brand-name medicines. It is a fast-growing business riding a wave that could shrink if the rules change.
Saved answer · last researched 15 Nov 2026